ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Authors: Andrew J. Souers, Joel D. Leverson, Erwin R. Boghaert, Scott Ackler, Nathaniel D. Catron, Jun Chen, Brian D. Dayton, Hong Ding, Sari H. Enschede, Wayne J. Fairbrother, David C.S. Huang, S.G. Hymowitz, Sha Jin, Seong Lin Khaw, Peter Kovar, Lloyd T. Lam, Jackie Lee, Heather Maecker, Kennan C. Marsh, Kylie D. Mason, Michael J. Mitten, Paul Nimmer, Anatol Oleksijew, Chang H. Park, Cheol‐Min Park, Darren C. Phillips, Andrew W. Roberts, Deepak Sampath, John F. Seymour, Morey L. Smith, Gerard M. Sullivan, Stephen K. Tahir, Chris Tse, Michael Wendt, Xiao Yu, John Xue, Haichao Zhang, Rod Humerickhouse, Saul H. Rosenberg, Steven W. Elmore - Nature Medicine 2013 cited by 3,018